U.S. markets close in 3 hours
  • S&P 500

    3,383.37
    -82.02 (-2.37%)
     
  • Dow 30

    27,521.97
    -813.60 (-2.87%)
     
  • Nasdaq

    11,290.03
    -258.25 (-2.24%)
     
  • Russell 2000

    1,597.60
    -42.90 (-2.62%)
     
  • Crude Oil

    38.47
    -1.38 (-3.46%)
     
  • Gold

    1,906.40
    +1.20 (+0.06%)
     
  • Silver

    24.49
    -0.18 (-0.75%)
     
  • EUR/USD

    1.1827
    -0.0041 (-0.34%)
     
  • 10-Yr Bond

    0.7990
    -0.0420 (-4.99%)
     
  • GBP/USD

    1.3023
    -0.0015 (-0.11%)
     
  • USD/JPY

    104.8400
    +0.1500 (+0.14%)
     
  • BTC-USD

    12,902.04
    -247.99 (-1.89%)
     
  • CMC Crypto 200

    257.34
    -6.08 (-2.31%)
     
  • FTSE 100

    5,792.01
    -68.27 (-1.16%)
     
  • Nikkei 225

    23,494.34
    -22.25 (-0.09%)
     

Estimating The Intrinsic Value Of Spectral Medical Inc. (TSE:EDT)

Simply Wall St
·6 mins read

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Spectral Medical Inc. (TSE:EDT) as an investment opportunity by estimating the company's future cash flows and discounting them to their present value. Our analysis will employ the Discounted Cash Flow (DCF) model. Believe it or not, it's not too difficult to follow, as you'll see from our example!

We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.

View our latest analysis for Spectral Medical

Is Spectral Medical fairly valued?

We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To start off with, we need to estimate the next ten years of cash flows. Seeing as no analyst estimates of free cash flow are available to us, we have extrapolate the previous free cash flow (FCF) from the company's last reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars:

10-year free cash flow (FCF) forecast

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Levered FCF (CA$, Millions)

CA$2.00m

CA$3.07m

CA$4.24m

CA$5.38m

CA$6.43m

CA$7.34m

CA$8.10m

CA$8.73m

CA$9.24m

CA$9.67m

Growth Rate Estimate Source

Est @ 75.78%

Est @ 53.54%

Est @ 37.98%

Est @ 27.08%

Est @ 19.46%

Est @ 14.12%

Est @ 10.38%

Est @ 7.76%

Est @ 5.93%

Est @ 4.65%

Present Value (CA$, Millions) Discounted @ 7.8%

CA$1.9

CA$2.6

CA$3.4

CA$4.0

CA$4.4

CA$4.7

CA$4.8

CA$4.8

CA$4.7

CA$4.6

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CA$39m

After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (1.7%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 7.8%.

Terminal Value (TV)= FCF2030 × (1 + g) ÷ (r – g) = CA$9.7m× (1 + 1.7%) ÷ (7.8%– 1.7%) = CA$161m

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CA$161m÷ ( 1 + 7.8%)10= CA$76m

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is CA$115m. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of CA$0.5, the company appears about fair value at a 5.4% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.

dcf
dcf

The assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Spectral Medical as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.8%, which is based on a levered beta of 1.017. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Moving On:

Whilst important, the DCF calculation shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. For Spectral Medical, we've compiled three essential factors you should assess:

  1. Risks: Be aware that Spectral Medical is showing 4 warning signs in our investment analysis , you should know about...

  2. Future Earnings: How does EDT's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the TSX every day. If you want to find the calculation for other stocks just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.